Advertisement

Renal Replacement Therapy in Critically Ill Cancer Patients

  • Kevin W. FinkelEmail author
  • Jaya Kala
Living reference work entry

Abstract

Acute kidney injury occurs commonly in patients with cancer and necessitates initiation of renal replacement therapy (RRT) in a subset of patients. Although RRT has been available since the 1950s, and despite great technologic improvements in the procedure, there remain several fundamental clinical questions regarding the proper use of RRT. The methods and controversies regarding RRT are reviewed in this chapter.

Keywords

Renal replacement therapy Dialysis Hemofiltration Convection Timing of dialysis Dose of dialysis Acute kidney injury Complications of dialysis Indications for dialysis 

References

  1. 1.
    Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9:12–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Pickering JW, James MT, Palmer SC. Acute kidney injury and prognosis after cardiopulmonary bypass: a meta-analysis of cohort studies. Am J Kidney Dis. 2015;65:283–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosner MH, Perazella MA. Acute kidney injury in patients with Cancer. N Engl J Med. 2017;377:500–1.PubMedGoogle Scholar
  4. 4.
    Lam AQ, Humphreys BD. Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol. 2012;7:1692–700.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Lameire N, Vanholder R, Van Biesen W, Benoit D. Acute kidney injury in critically ill cancer patients: an update. Crit Care. 2016;20:209.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Chuva T, Maximino J, Barbosa J, et al. Haematological malignancies and acute kidney injury requiring nephrology consultation: challenging the worst of the worst. Clin Kidney J. 2016;9:418–23.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Darmon M, Thiery G, Ciroldi M, Porcher R, Schlemmer B, Azoulay E. Should dialysis be offered to cancer patients with acute kidney injury? Intensive Care Med. 2007;33:765–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. Intensive Care Med. 1999;25:805–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Liu KD, Himmelfarb J, Paganini E, et al. Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol. 2006;1:915–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jaber BL. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. Am J Kidney Dis. 2008;52:272–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61:649–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Zarbock A, Kellum JA. Timing of initiation of renal replacement therapy in critically ill patients with acute kidney injury-reply. JAMA. 2016;316:1214.PubMedCrossRefGoogle Scholar
  14. 14.
    Friedrich JO, Wald R, Bagshaw SM, Burns KE, Adhikari NK. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care. 2012;16:R146.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Honore PM, Joannes-Boyau O, Boer W, Collin V. High-volume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif. 2009;28:1–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Joannes-Boyau O, Honore PM, Boer W, Collin V. Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation? Nephrol Dial Transplant. 2009;24:354–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Alsous F, Khamiees M, DeGirolamo A, Amoateng-Adjepong Y, Manthous CA. Negative fluid balance predicts survival in patients with septic shock: a retrospective pilot study. Chest. 2000;117:1749–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Salahuddin N, Sammani M, Hamdan A, et al. Fluid overload is an independent risk factor for acute kidney injury in critically ill patients: results of a cohort study. BMC Nephrol. 2017;18:45.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Goldstein SL. Fluid management in acute kidney injury. J Intensive Care Med. 2014;29:183–9.PubMedCrossRefGoogle Scholar
  21. 21.
    National Heart L. Blood institute acute respiratory distress syndrome clinical trials N, Wiedemann HP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–75.Google Scholar
  22. 22.
    Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296–304.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Gabriel DP, Caramori JT, Martin LC, Barretti P, Balbi AL. Continuous peritoneal dialysis compared with daily hemodialysis in patients with acute kidney injury. Perit Dial Int. 2009;29(Suppl 2):S62–71.PubMedGoogle Scholar
  27. 27.
    Ponce D, Berbel MN, Abrao JM, Goes CR, Balbi AL. A randomized clinical trial of high volume peritoneal dialysis versus extended daily hemodialysis for acute kidney injury patients. Int Urol Nephrol. 2013;45:869–78.PubMedCrossRefGoogle Scholar
  28. 28.
    Ponce D, Berbel MN, Regina de Goes C, Almeida CT, Balbi AL. High-volume peritoneal dialysis in acute kidney injury: indications and limitations. Clin J Am Soc Nephrol. 2012;7:887–94.PubMedCrossRefGoogle Scholar
  29. 29.
    George J, Varma S, Kumar S, Thomas J, Gopi S, Pisharody R. Comparing continuous venovenous hemodiafiltration and peritoneal dialysis in critically ill patients with acute kidney injury: a pilot study. Perit Dial Int. 2011;31:422–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Cullis B, Abdelraheem M, Abrahams G, et al. Peritoneal dialysis for acute kidney injury. Perit Dial Int. 2014;34:494–517.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Bagshaw SM, Berthiaume LR, Delaney A, Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008;36: 610–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Demirjian S, Teo BW, Guzman JA, et al. Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant. 2011;26:3508–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Wilson FP, Berns JS. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin Nephrol. 2012;77:329–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R. Extended daily Dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis. Am J Kidney Dis. 2015;66:322–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Davenport A, Will EJ, Davison AM. Early changes in intracranial pressure during haemofiltration treatment in patients with grade 4 hepatic encephalopathy and acute oliguric renal failure. Nephrol Dial Transplant. 1990;5:192–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Davenport A, Will EJ, Davison AM. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol. 1991;93:225–33.PubMedCrossRefGoogle Scholar
  37. 37.
    Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981;305:1176–81.PubMedCrossRefGoogle Scholar
  38. 38.
    Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002;346:305–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Network VNARFT, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.CrossRefGoogle Scholar
  41. 41.
    Investigators RRTS, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–38.CrossRefGoogle Scholar
  42. 42.
    van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol. 1996;7:145–50.PubMedGoogle Scholar
  43. 43.
    Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial. 2009;22: 141–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29:748–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol. 2014;9:2173–88.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009; 37:545–52.PubMedCrossRefGoogle Scholar
  47. 47.
    Section 5. Dialysis interventions for treatment of AKI. Kidney Int Suppl (2011). 2012;2:89–115.CrossRefGoogle Scholar
  48. 48.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33.PubMedCrossRefGoogle Scholar
  49. 49.
    Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004;128:875–9.PubMedGoogle Scholar
  50. 50.
    Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single Centre between 1975 and 1988. Q J Med. 1991;79:517–25.PubMedGoogle Scholar
  51. 51.
    Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22:1129–36.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143:777–84.PubMedCrossRefGoogle Scholar
  53. 53.
    Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013; 27:423–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28:4635–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947–59.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18:886–95.PubMedCrossRefGoogle Scholar
  57. 57.
    Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol. 2009;4:745–54.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Bridoux F, Carron PL, Pegourie B, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis Independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA. 2017;318:2099–110.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials. 2008;9:55.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Hutchison CCP, Heyne N, et al. European trial of free light chain removal by extended Haemodialysis in cast nephropathy (EuLITE); survival and renal outcomes. J Am Soc Nephrol. 2016;27:8A.CrossRefGoogle Scholar
  61. 61.
    Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395–403.PubMedCrossRefGoogle Scholar
  62. 62.
    Dooley MJ, Poole SG, Rischin D. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Ann Oncol. 2013;24:2746–52.PubMedCrossRefGoogle Scholar
  63. 63.
    Aronoff GBW, Berns J, et al. Drug prescibing in renal failure-dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Renal Diseases and HypertensionUTHealth Science Center at HoustonHoustonUSA

Personalised recommendations